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Abstract
Background: Educational interventions may be a strategy to increase human papillomavirus (HPV) vaccination
among female university students, but studies to date have shown mixed results. This study evaluated the effect
of MeFirst, an individually tailored, online educational intervention, on HPV vaccine-related knowledge,
vaccination intention, and uptake among previously unvaccinated female university students.
Methods: All female students aged 18–26 years who reported being unvaccinated against HPV at a midwestern
university were invited via email to enroll. Participants completed an online survey that assessed baseline HPV
vaccine-related knowledge, attitudes and vaccination intention. Participants (n= 661) were then randomized to
receive either an educational website automatically tailored to their baseline survey responses (MeFirst in-
tervention) or a standard CDC information factsheet on HPV vaccine (control). Vaccine uptake and repeat
knowledge and attitude measures were assessed with online surveys 3 months following the intervention and
analyzed using logistic regression models.
Results: HPV vaccine uptake was similar in both the MeFirst and control groups at 3 months following the
intervention ( p= 0.98). Three months after the intervention, the proportion of participants with high knowledge
regarding HPV vaccination increased from baseline (32% to 50%; p< 0.0001) but the proportion with favorable
intention was unchanged.
Conclusions: We found that an individually tailored, online educational tool had similar effects as a nontailored
factsheet on HPV-related knowledge, intention to HPV undergo vaccination, and HPV vaccine uptake among
previously unvaccinated female university students.
Introduction
Genital human papillomavirus (HPV) is the mostcommon sexually transmitted infection in the United
States, with adolescents and young adults at highest risk.1,2
Although most infections clear spontaneously, HPV causes
genital warts and cervical cancer and is associated with other
anogenital cancers and precancers.3 Since 2007, the CDC’s
Advisory Committee on Immunization Practices (ACIP) has
recommended routine HPV vaccination of girls ages 11–12
and ‘‘catch up’’ vaccination for females aged 13–26 years
who have not been previously vaccinated.3
Although the introduction of HPV vaccines has been as-
sociated with a dramatic reduction in vaccine-type HPV
prevalence (types 6, 11, 16, and 18) among females aged 14–
19 years, no similar change has been demonstrated among
females aged 20–24 years.4 National prevalence of at least
one vaccine-type HPV infection remained at 19%–20% in
this age group during the first four years after vaccine in-
troduction.4 Low levels of catch-up vaccination likely con-
tributed to the lack of observed effect. In 2011, only 29.5% of
females aged 19–26 had received any doses of HPV vaccine.5
Thus, young adult women remain an important target group
for HPV vaccination.
Female college students are one group of young adult
women for whom interventions could theoretically be de-
livered with low cost and effort through existing university
structures such as university health centers or campus email.
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Interventions to encourage HPV vaccination in this popula-
tion have had mixed results.6–10 One intervention, based on
sharing common HPV-vaccine decision stories in a narrative
format nearly doubled vaccine uptake at 2 months,6 and two
other interventions increased participant intention to be
vaccinated.7,8 However, two additional studies found no ef-
fect of educational interventions on vaccine uptake.9,10
Tailored health communications are modified based on
patient-specific characteristics to increase relevance to the
recipient;11 this approach has already shown promise among
HPV unvaccinated female college students.8 Since only 65%
of American women aged 18–24 years had a routine checkup
in 2009,12 and only 55% of women aged 15–24 accessed
sexual and reproductive health services between 2006 and
2010,13 relying on clinician recommendation is an extremely
limited strategy to increase HPV vaccination in this age
group. A recent meta-analysis found that tailored computer-
based interventions with decision, behavior, and/or emotional
support increased sexual health knowledge and self-efficacy
of participants.14 In college populations, tailored interven-
tions delivered via online platforms have been effective at
improving health knowledge and behavior in other research
areas.15,16 Because an online intervention could potentially
reach many women who otherwise may not receive health
messaging related to HPV vaccination, in 2010 our team be-
gan developing a novel, online, highly tailored educational
intervention for unvaccinated female college students.
The primary objective of this study was to determine the
impact of an individually tailored online educational inter-
vention (‘‘MeFirst’’) on HPV vaccine uptake among previ-
ously unvaccinated female university students, compared
with an untailored intervention. The secondary objective was
to quantify the effect of MeFirst on proposed mediators of
uptake, namely HPV vaccine-related knowledge, risk per-
ception, and intention to be vaccinated.
Materials and Methods
Subject pool and recruitment
A university Institutional Review Board approved all
methods (No. HUM00069032) and this study was registered
with clinicaltrials.gov (N0. NCT01769560) prior to study start.
Potential subjects were recruited among the female student
population at a large public midwestern university. All female
students aged 18–26 were sent three recruitment emails by the
Office of the Registrar in January 2013. The recruitment emails
specified the study was regarding HPV vaccination and that
female university students aged 18–26 who had never been
vaccinated against HPV were eligible to participate in a vol-
untary research study. Additional inclusion criteria included
either full or part-time student status at the university. Females
with prior receipt of any doses of HPV vaccine were ineligible
for the study. Eligible students were invited to participate in the
study and gave their informed consent by enrolling in the study.
Raffle entries were offered as incentives. Interested students
took a brief online eligibility survey prior to enrollment.
Baseline data collection
Upon enrollment, all participants were given a 144 ques-
tion baseline survey that included knowledge about HPV-
related disease and the HPV vaccine, opinions about the HPV
vaccine including perceptions of susceptibility, intentions to
receive the HPV vaccine, most recent medical visit, history of
Papanicolaou (Pap) smear, sexual history, and demographic
information. Knowledge about HPV and the HPV vaccine
was measured using 10 true/ false/don’t know statements.
Perceived risk of HPV infection and intention to be vacci-
nated were measured by agreement with the statements ‘‘I am
likely to get an HPV infection in my lifetime,’’ and ‘‘I intend
to get vaccinated against HPV,’’ respectively, using five-
point scales of strongly disagree/ disagree/ neutral/ agree/
strongly agree. Participants who did not complete the base-
line survey within 7 days of enrollment were sent up to two
automated reminder emails.
Randomization and interventions
Participants who completed the baseline survey were ran-
domized via an automated algorithm to either a MeFirst tailored
intervention website or a control website; their intervention site
was immediately available after survey completion with one
mouse click. The randomization was performed stratified by age
group (<21 or ‡21 years) to balance age of participants in each
arm. The control was a webpage of text from the CDC Vaccine
Information Statement on the quadrivalent HPV vaccine.17 The
MeFirst intervention website was a unique, tailored website
automatically configured for the individual participant based on
their baseline survey responses. It consisted of seven tailored
topic webpages that the participant could toggle through using a
navigation bar. The topic pages had factual information on HPV
and the HPV vaccine, including statistics on the incidence of
HPV infection and cervical cancer, risks associated with HPV
infection, costs of vaccination, safety and efficacy of the HPV
vaccine, and suggestions for how to talk to a doctor about the
vaccine. Previous qualitative work by this research group guided
MeFirst development. Tailoring was multifaceted but especially
focused on barriers to vaccination the participant had previously
endorsed, including perceived susceptibility (a list of tailoring
elements are available by request). Website tailoring also in-
cluded addressing the participant by their first name, using their
doctor’s name, and displaying background photos of young
women of the same self-identified racial background as the
participant. In total, up to 160 items could be tailored to the
participant on their individual MeFirst website. Participants who
received a MeFirst website were not exposed to a control
website.
Follow-up
Three months following randomization, participants were
emailed a request to log-in at their website to provide feed-
back on their decision of whether to get vaccinated against
HPV. After returning to the site, they were given a 37-
question survey that included the same knowledge, risk
perception, and intention items as the baseline survey and
additionally assessed HPV vaccine uptake. Participants who
did not complete the 3-month follow-up survey within 15
days were sent up to two automated reminder emails.
Primary outcome
HPV vaccine use was measured with the statement, ‘‘I
have received at least one dose of the HPV vaccine’’ with
possible responses of yes, no, or don’t know.


















































Knowledge was scored as the number of correct responses
out of 10 to yield a binary measure of a high level of knowledge
(‡9 correct answers) versus a low level of knowledge (<9
correct answers). Nine was chosen as the cutoff because it
included the 75th percentile of baseline scores. Barrier con-
traception use was analyzed as binary (high, always or mostly,
vs. low, occasionally or never). Intention and risk perception
were analyzed both as binary variables (positive, strongly
agree, agree, or neutral, vs. negative, disagree or strongly dis-
agree) and ordinal variables; results were similar, so only bi-
nary findings are presented for clarity. Vaccine uptake was
treated as a binary variable (yes vs. no or don’t know).
Statistical analysis
We conducted all analyses using SAS statistical soft-
ware, Version 9.3, of the SAS system for Windows (Copy-
rightª 2002–2010 SAS Institute Inc.; SAS and all other SAS
Institute Inc. product or service names are registered trade-
marks or trademarks of SAS Institute Inc., Cary, NC). Data
was checked for internal consistency and logic prior to fur-
ther analysis. An intention-to-treat analysis was performed;
participants who were randomized were analyzed regardless
of whether they actually viewed the intervention or not.
Descriptive statistics of all variables were calculated, in-
cluding means and standard deviations or frequencies as
appropriate. Randomization and potential bias in enrollment
and follow-up were each assessed by comparing character-
istics using a Wilcoxon Rank Sum, chi-squared, or Fisher
Exact test as appropriate.
Proportions of participants with high knowledge score,
positive risk perception, or positive vaccine intention were
compared between MeFirst and control groups using chi
squared tests at baseline and repeated at 3 months. For each of
these measures, change in proportion from baseline to 3 months
was tested within intervention groups using McNemar’s tests.
Unadjusted odds of vaccine uptake for MeFirst versus con-
trol participants were calculated using a logistic regression
model. Unadjusted logistic regression models were also used
to examine bivariate associations between each baseline
characteristic and HPV vaccine uptake. Multivariable logis-
tic regression models were then used to determine the inde-
pendent effect of the intervention, adjusting for factors found
to be statistically significant at the a = 0.10 level in the bi-
variate analyses. Results of logistic regression models were
expressed as odds ratios (ORs) and 95% confidence intervals
(95% CIs). All final statistical tests were two sided with
a = 0.05.
Results
Characteristics of the study sample at baseline
Selection of the sample population is presented in Figure 1.
Of enrolled participants, 85.8% completed the baseline sur-
vey and thus were randomized to one of two study groups.
Participants who completed the baseline survey did not differ
significantly on age, student enrollment status, or student type
from those who were eligible but did not enroll or complete
the baseline survey (data not shown).
There were no substantial differences between randomi-
zation groups in baseline demographic characteristics (see
Table 1). Most participants were single full-time students
with health insurance coverage. Relevant sexual and medical
history characteristics were also similar between randomi-
zation groups with the exception that more women random-
ized to MeFirst had engaged in anal sex ( p = 0.02). Among
the 70% of participants who reported a history of sexual
FIG. 1. Sample population.

















































activity, the majority of women had only one partner in the
past 6 months (66%) and more than three partners in their
lifetime (61%); 32.7% of all randomized participants in-
tended to be vaccinated at baseline, 26.4% were neutral, and
40.9% did not intend to be vaccinated.
Characteristics of respondents to three-month survey
Half of participants (332/661, 50.2%) responded to the
3-month follow-up survey and reported their HPV vaccine
status; the other half was lost to follow-up. Respondents to
Table 1. Demographic, Medical, and Sexual Characteristics of Study Participants
Who Completed the Baseline Survey
Characteristic Total (N = 661) MeFirst (N= 330) Control (N = 331) p-value
Demographic characteristics
Age, median years (SE) 21.0 (0.1) 21.0 (0.13) 21.0 (0.13) 0.88
Student enrollment, n (%) 0.33
Full-time 634 (95.9) 319 (96.7) 315 (95.2)
Part-time 27 (4.1) 11 (3.3) 16 (4.8)
Student standing, n (%) 0.31
Undergraduate 445 (67.3) 218 (66.1) 227 (68.6)
Graduate 182 (27.5) 98 (29.7) 84 (25.4)
Professional 34 (5.1) 14 (4.2) 20 (6.0)
Race, n (%) 0.25
Hispanic 30 (4.5) 17 (5.2) 13 (3.9)
Asian 98 (14.8) 56 (17.0) 42 (12.7)
Non-Hispanic black 36 (5.5) 21 (6.4) 15 (4.5)
Non-Hispanic white 445 (67.3) 21 (6.4) 15 (4.5)
Other/ multiracial 52 (7.9) 22 (6.7) 30 (9.1)
Health insurance, n (%) 0.48
UM SHIP or GradCare 106 (16.0) 58 (8.8) 48 (7.3)
Parent’s private 438 (66.3) 212 (32.1) 226 (34.2)
Medicaid 10(1.5) 5 (0.8) 5 (0.8)
Other insurance 41 (6.2) 17 (2.6) 24 (3.6)
None 43 (6.5) 26 (3.9) 17 (2.6)
Don’t know/missing 23 (3.5) 12 (1.8) 11 (1.7)
Employment, n (%) 0.14
Full-time 55 (8.3) 35 (10.6) 20 (6.0)
Part-time 323 (48.9) 159 (48.2) 164 (49.6)
Unemployed 280 (42.4) 134 (40.6) 146 (44.1)
Missing 3 (0.5) 2 (0.6) 1 (0.3)
Marital status, n (%) 0.65
Single 545 (82.5) 268 (81.2) 277 (83.7)
Married 32 (4.8) 16 (4.9) 16 (4.8)
Separated 1 (0.2) 0 1(0.3)
In unmarried couple 82 (12.4) 45 (13.6) 37 (11.2)
Missing 1 (0.2) 1(0.3) 0
Medical history
Gets regular checkups, n (%) 374 (56.6) 181 (54.9) 193 (58.3) 0.11
Health care visit in past 12 months, n (%) 540 (81.7) 258 (78.2) 282 (85.2) 0.07
Ever had a Papanicolaou (Pap) test, n (%) 292 (44.2) 144 (43.6) 148 (44.7) 0.81
Pap in past 12 months, n (%) 205 (31.0) 107 (32.4) 98 (29.6) 0.53
Ever had an abnormal Pap test, n (%) 39 (5.9) 24 (7.3) 15 (4.5) 0.27
Ever had HPV, n (%) 16 (2.4) 9 (2.7) 7 (2.1) 0.77
Ever had STI (non-HPV), n (%) 23 (3.5) 12 (3.6) 11 (3.3) 0.94
Smoked in past 7 days, n (%) 34 (5.1) 14 (4.2) 20 (6.0) 0.38
Sexual history
Ever had sexual intercourse, n (%) 463 (70.1) 224 (67.8) 239 (72.2) 0.32
Age at sexual debut, median years (SE) 18.0 (0.1) 18.0 (0.2) 18.0 (0.1) 0.41
Frequency of barrier method use, n (%) 0.78
Never 104 (22.3) 53 (23.4) 51 (21.3)
Occasionally 71 (45.2) 31 (13.7) 40 (16.7)
Mostly 133 (28.5) 66 (29.1) 67 (27.9)
Always 153 (32.8) 73 (32.2) 80 (33.3)
Missing 6 (1.3) 4 (1.8) 2 (0.8)
HPV, human papilloma virus; SE, standard error; STI, sexually transmitted infection; UM SHIP, University of Michigan Student Health
Insurance Plan.

















































the 3-month survey were significantly racially different from
nonrespondents, particularly among MeFirst participants
(chi-squared = 11.61, p= 0.02). Proportionally fewer Asian
women took the 3-month survey, and proportionally more
Hispanic and white women did take it. Participants who
smoked in the week before intervention were less likely to
follow-up 3 months later (chi-squared = 9.16, p = 0.01).
Among participants who had the MeFirst intervention, but
not among those who had the control intervention, partici-
pants with lower baseline intentions were more likely to re-
spond to the three months survey (Wilcoxon = 27,203,
p = 0.03) than those with higher baseline intention.
Outcomes at three months following the intervention
Three months after intervention, there was no difference in
HPV vaccine uptake among participants randomized to the
MeFirst intervention compared with controls (chi-squared=
0.09, p= 0.76); 8.4% of all participants initiated the vaccine
series (see Figure 2). Of those who received the first dose of
the HPV vaccine series, 42.9% (6/14) also received a second
dose in each study group. The proportion of all participants
with a high level of knowledge increased from 32% at
baseline to 50% at three months (McNemar’s statistic = 33.4;
p < 0.0001). This increase in knowledge is not associated with
intervention assignment. Risk perception and intention to be
vaccinated did not change significantly from baseline to 3
months in either group. Of participants who intended to un-
dergo HPV vaccination at baseline, 82.4% remained unvac-
cinated 3 months later.
Correlates of HPV vaccine uptake at three months
following intervention
Knowledge change was not significantly associated with
HPV vaccine uptake at 3 months on bivariate analysis (OR
0.92; 95% CI 0.78–1.09); the variables that were significantly
associated with HPV vaccine uptake were nonemployment
(OR 3.28; 95% CI 1.44–7.50), low sexual barrier use (OR
4.71; 95% CI 1.65–13.47), and high baseline intention to be
vaccinated (OR 5.10; 95% CI 2.22–11.70). In the final lo-
gistic regression model, which included the MeFirst inter-
vention and these significant covariates, nonemployment
(OR = 3.60; 95% CI 1.27–10.20), low frequency use of sexual
barriers (OR = 7.09; 95% CI 2.27–22.14), and high baseline
intention to be vaccinated (OR 5.84, 95% CI 2.04–16.77) all
remained significant. However, the effect of the MeFirst in-
tervention on HPV vaccine uptake at 3 months remained
nonsignificant (OR 0.92; 95% CI 0.34–2.54).
Discussion
We found no difference in HPV vaccine uptake between
intervention arms, suggesting this individually tailored in-
tervention had no greater effect than the CDC Vaccine In-
formation Statement on HPV vaccine initiation among our
study sample of unvaccinated female university students. The
incidence of HPV vaccine initiation in our sample, 8% over a
3-month period, is consistent with rates among control par-
ticipants in previously reported unvaccinated student cohorts
of 6–12% with 2–10 months of follow-up.6,9,10 While this
study showed no difference in effect of individually tailored
and nontailored educational materials on vaccine uptake
rates, we also found overall low uptake rates in both groups. It
remains unclear whether individually tailored and/or stan-
dard HPV education can improve vaccine uptake enough to
have a population impact.
Our secondary outcomes and multivariate model may pro-
vide clues about why this intervention was not associated with
vaccine uptake. First, both intervention groups showed signif-
icant improvement in knowledge at 3 months following the
intervention, but knowledge change was unassociated with
uptake; this would suggest, as others have,18 that increasing
knowledge by itself is insufficient to increase vaccine uptake
(i.e., behavior change) in the absence of additional measures
such as explicit provider endorsement of vaccination or sys-
tems improvement to provide immediate vaccination once
readiness to vaccinate is identified. Second, intention was sig-
nificantly associated with uptake; MeFirst may have failed to
affect uptake because it failed to impact intention. The adult
population in the study may have already been firm in their
intentions about vaccination, highlighting the need for contin-
ued work increasing uptake among the pediatric population.
Comparison with previous interventions
The value of educational interventions to increase HPV
vaccination among female university students is unclear,
possibly because knowledge is not a strong predictor of
vaccine behavior. Although initial cross-sectional studies
after vaccine approval showed limited positive associations
between HPV-related knowledge and intention to be vacci-
nated against HPV in young female adults,19–21 more recent
investigations have shown that knowledge is not associated
with interest in vaccination or vaccine uptake after adjust-
ment for other factors.18,22 Factually driven educational in-
terventions targeting participant knowledge have shown to
have some impact on intention to be vaccinated7 but have not
been associated with change in actual vaccine uptake.9,10
Taken together, these studies suggest that a knowledge-
focused approach may impact immediate vaccine intent, but
does not appear to affect behavior.
Educational interventions that have specifically targeted
the female university population in some way have been
more promising. Gerend et al. reported that additional edu-
cational information tailored to the individual participant’s
FIG. 2. HPV vaccine uptake at 3 months, MeFirst versus
control.

















































perceived barriers increased intention to be vaccinated versus
standard CDC-based information.8 Hopfer reported that
vaccine uptake doubled among participants randomized to a
combined peer–expert vaccine decision narrative video
compared with control.6 This intervention was based on
culture-centric narrative theory6 as described by Larkey and
Hecht23 and focused on HPV susceptibility, self-efficacy,
vaccine safety, and vaccine use regardless of sexual experi-
ence.6 These personally or culturally tailored approaches
may work by providing information that participants find
particularly relevant.
MeFirst was similar to these successful interventions in
several ways despite our null findings. Our intervention was
substantially more tailored than that of Gerend et al.;8 we
tailored on demographics, attitudes, and behavioral variable
in addition to perceived barriers. We do not know if MeFirst
increased immediate intention to be vaccinated, as Gerend’s
tailored intervention did,8 but any effects it had immediately
did not translate to the more important outcome of vaccine
uptake after 3 months. MeFirst provided information on the
same four themes Hopfer addressed, but presented this in-
formation in an educational question and answer style with-
out personal stories or any particular narrator; ours may have
been less efficacious because of this difference in approach.
However, only one of three of Hopfer’s narrative interven-
tions was effective,6 indicating that a better understanding of
the mechanisms of HPV vaccine decision making is still
necessary to develop useful interventions.
Strengths and limitations of the study
The strengths of this study include the randomized, con-
trolled design and the use of a novel, individually tailored,
online intervention that could be easily adapted to other
settings. If this study had shown an important increase in
HPV vaccination using MeFirst, other universities could have
easily used it as a cost-effective measure to increase vaccine
uptake among their students. Several limitations of this study
should be considered. First, our study may have been biased
by participant self-selection. Although a significant propor-
tion of invited students were likely vaccinated and thus in-
eligible, a large proportion (92%) of students who were
invited to participate did not respond, even after three email
invitations. If proportionally more women who were already
set in their intention to undergo HPV vaccination enrolled
than in the general population, our study would have been
biased towards the null. However, it was somewhat reassur-
ing that participants who completed the baseline survey were
similar on key demographic characteristics as those who were
eligible but did not enroll or complete the baseline survey.
Second, we had substantial loss to follow-up. Our pre-
intervention survey was long, which may have fatigued
participants and contributed to attrition before the 3-month
survey. All of these factors limit our ability to generalize our
findings on the effectiveness of an individually tailored in-
tervention for HPV vaccine uptake to broader populations.
Implications for future research
Increasing vaccine uptake among young adults likely re-
quires a multifaceted approach. In this study, the adjusted
odds of initiating the HPV vaccine series were nearly six
times higher for those who intended to get the vaccine at
baseline versus those who were not sure or did not intend to
get it, yet over 80% of participants who intended to get
vaccinated remained unvaccinated 3 months later. Other
factors, such as practical barriers, must be important. Since
the Affordable Care Act now mandates no-cost sharing on the
HPV vaccine for eligible children and adults for those with
non-grandfathered private insurance,24 there is an ongoing
natural experiment of the impact of decreasing the practical
barrier of cost. Future research efforts could consider inter-
ventions to increase convenience of vaccine administration,
like on-site vaccination at community events, such as fresh-
man move-in day for university communities.
Interventions to increase catch-up HPV vaccination must
move beyond female university students because other young
adults, including nonstudents and men, may be at higher risk
for nonvaccination. Large college surveys have reported fe-
male student vaccination rates of 57% in 200922 and 55% in
201025 compared with 21% of all females aged 19–26 years
in 2010.26 Although CDC data is not yet available for 2012,
the available information suggests that vaccine uptake has
been low for men since the ACIP recommended male routine
vaccination.27 Future intervention studies in young adults
should include a broader range of participants to increase
utility and generalizability of the research.
Implications for practice
Cumulatively, the current evidence suggests that the
resources invested in developing highly tailored interven-
tions to improve acceptance of HPV vaccination may be
better reassigned to horizontal integration of care delivery
with routine identification of those in need of vaccination at
multiple points of entry into the university health system,
offering HPV vaccination to those in need at any point of
entry and facilitating vaccine service delivery within the
same visit, if possible, those who are ready to be vacci-
nated. For those who are in need, but not ready to be vac-
cinated, rigorously developed educational material such as
a standard CDC information factsheet on HPV vaccine may
be sufficient.
Conclusions
In this randomized controlled trial, an individually tailored
online intervention was not associated with a difference in
uptake of HPV vaccine among female university students 3
months post-intervention compared with the standard CDC
HPV Vaccine Information Statement. Both intervention
groups showed increased knowledge from baseline, but this
change in knowledge did not mediate uptake. We found no
evidence that HPV vaccine uptake among unvaccinated fe-
male university students was affected by use of this indi-
vidually tailored online intervention. Future interventions
should target both sexes and consider decreasing practical
barriers to uptake. More research could help determine
whether investing significant time and money on tailored
educational interventions is valuable for increasing HPV
vaccine uptake among female university students.
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